Open Care

Global disease burden is severe and increasing. As a global population, we face ever-increasing challenges around our health and wellbeing. We are a global community and with the rise of internationalised economies and ease of travel, communicable diseases are an increasing risk to everyone. We are seeing a rise in the number of global pandemics through opportunistic pathogens that threaten countless lives and economies. The World Health Organisation has prioritised a list of serious pathogens that are most likely to cause severe outbreaks in the near future. Outbreaks threaten the health of humanity and our global economies whether from naturally emerging disease or potential bioterrorism-related threats that are yet to occur. It is clear that we need a new way to fight infectious disease and that's exactly what we are building with Immubio. Immubio brings together core aspects of health and a deep understanding of immunity that all work together to promote, restore and maintain health. Our platform includes targeted immunisation development using nanoparticles for infectious diseases combined with a simplified oral liquid delivery system that reduces costs and increases adoption. Open Care is committed to providing targeted immunisations at scale that are effective at reducing disease burden, that provide a high level of safety and are less costly than traditional immunisations.